Strong Smoke-Free Volume Growth
Smoke-free product shipments rose 12.8% year-over-year, adding ~20 billion units (179 billion total smoke-free units in 2025). IQOS shipments grew ~11% (to ~155 billion units) with adjusted in-market sales (IMS) growth accelerating to ~12% in Q4 and ~10.5% for the full year.
Material Profitability and Margin Expansion
Adjusted operating income grew 11.8% in dollar terms to $16.4 billion; organic operating income rose 10.6% with organic margin expansion of +140 bps. Adjusted operating income margin reached 40.4%. Gross margin expanded organically by ~220 bps to >67%; smoke-free adjusted gross margin increased ~270 bps to ~69.5%.
Record Revenue Mix Shift to Smoke-Free
Total net revenues exceeded $40 billion in 2025, with smoke-free products representing ~41.5% (~$17 billion) of net revenue and smoke-free gross contribution doubling over five years to ~43% of total PMI.
Adjusted Diluted EPS and Cash Generation
Adjusted diluted EPS rose ~15% in dollar terms (currency-neutral +14.2%) to $7.54, at the high end of guidance. Operating cash flow was strong at $12.2 billion (matching 2024). Management targets further cash flow acceleration (~€13.5 billion at prevailing rates) and deleveraging to close to 2x net leverage by end-2026 (2.5x at year-end 2025).
ZYN and Multi-Category Execution
ZYN shipments grew ~36–37% globally with expansion into ~56 markets (added ~19 markets). ZYN had ~40% PMI pouch-category share and significant US share gains (leading premium share; US shipment growth despite supply constraints). E-vapor brand VIVE doubled shipments for the year and improved profitability; VIVE is present in ~47 markets.
Geographic and Market Milestones
106 markets now have PMI smoke-free products (52 deployed category strategy). 27 markets exceeded 50% smoke-free net revenue; 8 markets exceeded 75% (including the US). Europe surpassed 50% smoke-free net revenue for the year. Estimated legal-age smoke-free users reached ~43.5 million (up ~10 million in two years).
Delivered and Accelerated Strategic Targets
Company achieved its three-year CAGR targets for organic operating income and currency-neutral EPS in two years. Management renewed medium-term targets for 2026–2028: organic net revenue CAGR 6–8%, organic operating income 8–10%, adjusted diluted EPS 9–11% (constant currency). 2026 guidance: organic net revenue +5–7%, organic OI +7–9%, currency-neutral EPS +7.5–9.5% (translating to $8.09–$8.54 including ~€ currency benefit).
Cost Savings and Efficiency
Delivered roughly $1.5 billion of growth cost savings since 2024 and remains on track for a $2 billion objective in the 2024–2026 period. Management expects further efficiency gains, including future AI-driven productivity improvements.